Analytics
Resolved Yes on 9 Jun 2025.
$22.55K traded over the market's life.
2 wallets still hold shares. Winners redeem theirs after settlement, so what is left is mostly the losing side.
Polymarket record as of Jun 11, 12:25 AM UTC
Daily closes of the Yes price, Polymarket CLOB, 1 point, 9 Jun 2025, chart shows 68%–80%
| Observed | Yes price |
|---|---|
| 9 Jun 2025 | 74.0% |
Winners have redeemed their shares, so most of what is left is the losing side.
Open a trader’s name to inspect the wallet’s available P&L, positions and recorded trades, with source dates and coverage. A large position alone does not establish a winning track record.
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Merck’s biologics license application (BLA) for clesrovimab (MK‑1654) as a preventive treatment for respiratory syncytial virus (RSV) in infants by June 17, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No". This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL), explicitly declines to approve the application. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
Official listing: polymarket.com/event/fda-approves-mercks-clesrovimab-infant-rsv-prevention-mk1654
New to prediction markets? How to read a market page
